info:eu-repo/semantics/article
Structure-Activity Relationship Study of an Alkynylphosphonate and a Vynilphosphonate Analogues of Calcitriol
Fecha
2021-08-18Registro en:
Grioli, Silvina Mariela; Alonso, Eliana Noelia; Mascaro, Evangelina; Stabile, Santiago Armando; Ferronato, María Julia; et al.; Structure-Activity Relationship Study of an Alkynylphosphonate and a Vynilphosphonate Analogues of Calcitriol; Bentham Science Publishers; Medicinal Chemistry; 17; 3; 18-8-2021; 230 - 246
1573-4064
1875-6638
CONICET Digital
CONICET
Autor
Grioli, Silvina Mariela
Alonso, Eliana Noelia
Mascaro, Evangelina
Stabile, Santiago Armando
Ferronato, María Julia
Quevedo, Mario Alfredo
Radivoy, Gabriel Eduardo
Facchinetti, Maria Marta
Vitale, Cristian Alejandro
Curino, Alejandro Carlos
Resumen
Background: 1α,25-dihydroxy vitamin D3 (calcitriol) shows potent growth-inhibitory properties on different cancer cell lines, but its hypercalcemic effects have severely hampered its therapeutic application. Therefore, it is important to develop synthetic calcitriol analogues that retain or even increase its antitumoral effects and lack hypercalcemic activity. Based on previous evidence of the potent antitumor effects of the synthetic alkynylphosphonate EM1 analogue, we have now synthesized a derivative called SG. Objective: The aim of the present work is to evaluate the calcemic activity and the antitumor effect of SG, comparing these effects with those exerted by calcitriol and with those previously published for EM1. In addition, we propose to analyze by in silico studies, the chemical structure-biological function relationship of these molecules. Methods: We performed the synthesis of vinylphosphonate SG analogue; in vitro assays on different cancer cell lines; in vivo assays on mice; and in silico assays applying computational molecular modeling. Results: The SG compound lacks hypercalcemic activity, similar to the parent compound EM1. However, the antitumor activity was blunted, as no antiproliferative or anti-migratory effects were observed. By in silico assays, we demonstrated that SG analogue has a lower affinity for the VDRligand- binding domain than the EM1 compound due to lack of interaction with the important residues His305 and His397. Conclusion: These results demonstrate that the chemical modification in the lateral side chain of the SG analogue affects the antitumoral activity observed previously for EM1 but does not affect the calcemic activity. These results contribute to the rational design and synthesis of novel calcitriol analogues.